Kolon Life Science Inc (102940) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.007x

Based on the latest financial reports, Kolon Life Science Inc (102940) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.58 Billion ≈ $1.75 Million USD) by net assets (₩346.41 Billion ≈ $234.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Kolon Life Science Inc balance sheet independence to measure how much of total assets are equity-financed.

Kolon Life Science Inc - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Kolon Life Science Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 102940 operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Kolon Life Science Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kolon Life Science Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
eWork Group AB ST:EWRK	-0.381x
Samick Thk KO:004380	0.064x
FCR Immobilien AG XETRA:FC9	0.076x
Garuda Metalindo Tbk PT JK:BOLT	-0.092x
Shinsegae I&C KO:035510	0.050x
HB Technology CO.LTD KQ:078150	0.041x
Affluent Medical SAS PA:AFME	-0.319x
Salasar Techno Engineering Limited NSE:SALASAR	0.024x

Annual Cash Flow Conversion Efficiency for Kolon Life Science Inc (2014–2024)

The table below shows the annual cash flow conversion efficiency of Kolon Life Science Inc from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see 102940 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩149.34 Billion ≈ $101.20 Million	₩-14.08 Billion ≈ $-9.55 Million	-0.094x	+47.78%
2023-12-31	₩137.67 Billion ≈ $93.30 Million	₩-24.87 Billion ≈ $-16.85 Million	-0.181x	-45.27%
2022-12-31	₩167.72 Billion ≈ $113.66 Million	₩-20.85 Billion ≈ $-14.13 Million	-0.124x	+23.64%
2021-12-31	₩99.41 Billion ≈ $67.37 Million	₩-16.19 Billion ≈ $-10.97 Million	-0.163x	-29.16%
2020-12-31	₩57.96 Billion ≈ $39.28 Million	₩-7.31 Billion ≈ $-4.95 Million	-0.126x	+36.89%
2019-12-31	₩101.02 Billion ≈ $68.46 Million	₩-20.18 Billion ≈ $-13.68 Million	-0.200x	-555.43%
2018-12-31	₩446.15 Billion ≈ $302.35 Million	₩-13.60 Billion ≈ $-9.22 Million	-0.030x	-100.45%
2017-12-31	₩545.41 Billion ≈ $369.62 Million	₩-8.29 Billion ≈ $-5.62 Million	-0.015x	-114.05%
2016-12-31	₩259.79 Billion ≈ $176.05 Million	₩28.11 Billion ≈ $19.05 Million	0.108x	-29.56%
2015-12-31	₩135.44 Billion ≈ $91.79 Million	₩20.81 Billion ≈ $14.10 Million	0.154x	+72.96%
2014-12-31	₩136.17 Billion ≈ $92.28 Million	₩12.10 Billion ≈ $8.20 Million	0.089x	--

About Kolon Life Science Inc

KQ:102940 Korea Pharmaceuticals

Market Cap

$110.48 Million

₩163.02 Billion KRW

Market Cap Rank

#18756 Global

#838 in Korea

Share Price

₩14290.00

Change (1 day)

+7.44%

52-Week Range

₩13300.00 - ₩70800.00

All Time High

₩163572.85